OPEN APP
Home >Companies >News >Biocon Biologics receives 555 Cr Capital Injection from ADQ
Shares of Biocon Ltd lost 1.11% to close at  ₹454.95 on BSE (Mint )
Shares of Biocon Ltd lost 1.11% to close at 454.95 on BSE (Mint )

Biocon Biologics receives 555 Cr Capital Injection from ADQ

ADQ will invest 555 crore for a 1.80% minority stake in the biosimilar business, valuing Biocon Biologics at a post money valuation of $4.17 billion

Mumbai: Biocon Ltd on Thursday said that the board of its subsidiary Biocon Biologics Ltd had approved a primary equity investment of 555 crore by Abu Dhabi based ADQ.

Biocon Biologics is a fully integrated ‘pure play’ biosimilars organization.

According to a release to the exchange, ADQ will invest 555 crore for a 1.80% minority stake in the biosimilar business, valuing Biocon Biologics at a post money valuation of $4.17 billion.

“This investment is an endorsement of the value that Biocon Biologics business has built as a fully integrated pure-play biosimilars company and will enable us to expand our capabilities further," said Kiran Mazumdar-Shaw, executive chairperson of Biocon.

In November, Biocon Biologics Ltd had approved 1, 125 crore capital injection from Goldman Sachs.

Earlier in July, Tata Capital PE arm picked a minority 0.85% stake for $30 million in the company and in January 2020, True North acquired 2.44% stake in the company for 536.25 crore, or around $75 million.

Shares of Biocon Ltd lost 1.11% to close at 454.95 on BSE, while the benchmark index, Sensex lost 0.17% to close at 48093.32 points.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
×
Edit Profile
My Reads Redeem a Gift Card Logout